Trial Profile
An Open-label, Randomized, Controlled, Multicenter, Phase II Study Evaluating Safety and Efficacy of Intratumorally Administered Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy, Compared to Sunitinib Post-nephrectomy in Metastatic Renal Cell Carcinoma Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Dec 2023
Price :
$35
*
At a glance
- Drugs Ilixadencel (Primary) ; Sunitinib
- Indications Renal cell carcinoma
- Focus Proof of concept; Therapeutic Use
- Acronyms MERECA
- Sponsors Immunicum; Mendus
- 22 Dec 2023 According to a Mendus media release, long term follow up completed in this trial. Final results of the MERECA trial confirm the decision not to pursue mRCC as a possible indication for ilixadencel.
- 22 Dec 2023 Results published in the Mendus Media Release.
- 01 Jun 2022 Primary endpoint of 18 months survival rate after randomization for the intermediate-risk mRCC patients in the two treatment arms has not been met, according to results published in the European Urology Open Science.